PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
Article in Journal of Neurology (June 2021)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Article in Journal of Neurology (June 2021)
Book chapter (October 2019)
Book chapter (November 2017)